What type of study is this?

This is a Pre-Registered Trial study.

December 8, 2025BloodOpen Access

Mitapivat improves red blood cell integrity by reducing membrane ubiquitination accumulation

View Full Paper

Ask AI

Bookmark

Authors

SGShouguo GaoNational Institutes of Health XWXunde WangNational Institutes of Health

Discussion

Member takes

Implication

Observational analysis showed mitapivat improves hemoglobin levels and reduces oxidative stress in sickle cell disease patients, indicating better RBC integrity.

Key Points

Red blood cell integrity improved while reducing ubiquitination levels in sickle cell disease patients.
Patients exhibited a significant increase in hemoglobin after mitapivat administration enhancing bioenergetics.
Densitometry analysis showed a notable decrease in membrane ubiquitination levels alongside increased ATP production.
Findings suggest a link between reduced oxidative stress and improved RBC membrane integrity with mitapivat treatment.

Cite This Study

Gao et al. (2025) studied this question.

synapsesocial.com/papers/69362f7d4fa91c937236e476 https://doi.org/10.1182/blood-2025-1146

View Full Paper

Ask AI

Bookmark

Implication

Observational analysis showed mitapivat improves hemoglobin levels and reduces oxidative stress in sickle cell disease patients, indicating better RBC integrity.

Mitapivat improves red blood cell integrity by reducing membrane ubiquitination accumulation

Discussion

Member takes

Implication

Key Points

Cite This Study

Mitapivat improves red blood cell integrity by reducing membrane ubiquitination accumulation

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider